bio2016 biosimilars bio one-on-one partnering_june 6th-9th_san fransisco
TRANSCRIPT
BIO One-on-One Partnering™June 6-9, 2016 San Francisco, CA
Custom Biologics™Design and validation of functional bioassays.
3
-Functional Assays
-Binding
-Potency
-Immunogenicity
3 Divisions
-NCE, Oligos, Peptides
-Pk/Tk studies
-Bioanalytical LCMSMS
-Genetic biomarkers
-SNP analysis
-Gene expression
Large Molecules Small Molecules Molecular Diagnostics
custombiologics.com
Quality Assurance Unit
• Oversees and implements GLP-compliant Quality System– Based on FDA guidelines 21 CFR Parts 11 and 58
• Comprehensive reporting
• Health Canada Drug Establishment License (Fall 2016)
4custombiologics.com
Large Molecules-BIOSIMILARSQualified/Validated Assays:
• Adalumimab
• Bevacizumab
• Cetuximab
• Etanercept
• Infliximab
• Ranibizuimab
• Rituximab
• Trastuzumab
• IFN /
• GCSF
• PTH
In Development:
• Abatacept
• Canakinumab
• Certolizumab pegol
• Daclizumab
• Denosumab
• Eculizumab
• Erythropoietin
• Factor VIII
• Golimumab
• Insulin
• Ipilimumab
• Natalizumab
• Tocilizumab
• Ustekinumab
5custombiologics.com
Biologics Functional Activity Testing
• Potency, cytotoxicity, proliferation
• CDC/ADCC
• FcɣR binding assays
• Pk/Tk studies (pre-clinical and clinical)
• Immunogenicity Assays (ADA/Nab)
• Cytokine release
• Stability/Lot release testing
• Statistical analysis (parallelism, 4/5PL)
6custombiologics.com
Functional Assay Testing Platforms
• Absorbance, fluorescence, luminescence, ECL• Flow cytometry• Surface Plasma Resonance• qPCR• NMR (academic collaboration)
7custombiologics.com
Regulatory Compliance
8
• Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. FDA Guidance for Industry. April 2015
• Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Product. FDA Guidance for Industry. April 2016
• USP <1032> 2012. Design and Development of Biological Assays. USP 35–NF 30:162
• USP <1033>2012. Biological Assay Validation. USP 35–NF 30:5174.
• USP <1034> 2012. Analysis of Biological Assays. USP 35–NF 30:5186.
• International Conference on Harmonization. ICH Topics Q6B. Guidance for Industry: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products18 August 1999
• Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues
custombiologics.com
Accurate and Sensitive Bioassays
A. Originator vs. biosimilar B. Biosimilar potency level evaluation
9
Dose response Originator vs Biosimilar
-1 0 1 2 3 4800
1000
1200
1400
1600
1800
2000
Log [Ranibizumab] (ng/mL)
RFU
Originator
Biosimilar
Log [Biosimilar]
Sign
al
0 1 2 34500
5500
6500
7500
100%
50%
Log [Biosimilar]
Sign
al
0 1 2 33000
4000
5000
6000
7000
100%
141%
Log [Biosimilar]
Sign
al
0 1 2 34500
5500
6500
7500
100%
71%
Log [Biosimilar]
Sign
al
0 1 2 33000
4000
5000
6000
7000
100%
200%
Cell-based Bioassay - Potency Levels
custombiologics.com
Biologics Support and Characterization
• Cell banking (MCB/WCB)
– Mycoplasma testing (validation pending)
• Protein analytical characterization
– SDS-PAGE
– Western blotting
– IEF
– Gel documentation system
• Host cell residual contamination assays
– Host Cell Protein (HCP)
– Host Cell DNA (HCD)
10custombiologics.com
Residual qPCR host cell DNA assays
• CHO cells (1.28 pg/mL)
• Goat’s milk (5.0 pg/mL)
• Tobacco plant (1.0 pg/mL)
• Plasmid DNA (0.1 pg/mL)
• E.coli (1 pg/mL)
• Multiplex HCD assays
11custombiologics.com
Biosafety Level 2 (HPTA License)
– Biological safety cabinets– CO2 incubators – LN2 storage– Fridge/Freezers– 24/7 monitoring
12custombiologics.com
Working with us
• Project managers: PhD-trained scientists directly involved with the project.
• Knowledgeable on the scientific and regulatory issues associated with assay design, validation and GMP testing.
Responsive. Thorough. Committed.
13custombiologics.com
14
8,000 sqft GLP-compliant bioanalytical testing facility
custombiologics.com
Thank You